Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has secured an agreement with a leading group purchasing organization (GPO) that will provide coverage for TONMYA (cyclobenzaprine HCl sublingual tablets) to approximately 35 million U.S. commercial lives, or about 20% of the commercial market. The agreement, effective May 1, 2026, includes standard utilization management criteria and marks a significant step in expanding patient access to the company's FDA-approved, non-opioid fibromyalgia treatment.
The GPO deal is part of Tonix's broader strategy to secure coverage across commercial and government channels. The company already has Medicaid coverage in 38 states, representing approximately 55 million lives, and continues to pursue additional coverage. TONMYA, approved in 2024, is the first new treatment for fibromyalgia in more than 15 years, offering an alternative to opioids for managing this chronic pain condition that affects an estimated 10 million people in the United States.
Fibromyalgia is characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties, and has historically been treated with a limited set of therapies. TONMYA's sublingual formulation of cyclobenzaprine, a muscle relaxant, provides a novel delivery mechanism designed for rapid absorption and potentially fewer side effects. The GPO agreement is expected to improve patient access, potentially reducing reliance on opioids and addressing a significant unmet medical need.
For business leaders and healthcare investors, this development signals growing commercial traction for Tonix's CNS portfolio. The company has built a commercial infrastructure to support TONMYA alongside its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is also exploring TONMYA's potential in Phase 2 trials for major depressive disorder and acute stress disorder, which could broaden its market impact.
The fibromyalgia treatment market is estimated at over $2 billion annually, and TONMYA's entry with a novel mechanism could capture significant share, especially as payers seek non-opioid options. The GPO agreement covering 35 million lives represents a critical access point, potentially influencing prescribing patterns and patient outcomes.
Tonix's pipeline extends beyond fibromyalgia. The company is advancing TNX-2900 for Prader-Willi syndrome, a rare genetic disorder, and immunology programs including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention. These programs highlight Tonix's focus on high-unmet-need areas in CNS and immunology.
The full press release is available at https://ibn.fm/ShicX. For the latest news on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP.
